Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 28, 2011

View Archived Issues

Sanofi-aventis profiles progress of fourth quarter 2010

Additional phase II data reported on paclitaxel nanoparticles in urothelial cancer

Aestus begins phase II trial of ATx08-001 for neuropathic pain after shingles outbreak

Lux Biosciences begins enrollment in phase III voclosporin trial in uveitis

Global Health Ventures begins clinical development of X-Excite in E.U.

Lee's Pharma receives rights to Gaslon N in China

NCI develops anticancer monoclonal antibodies targeting mesothelin

Phase II pazopanib trial in urothelial cancer closed due to lack of activity

Rare Disease Day / Recently launched orphan drugs

Everolimus is active in patients with transitional cell carcinoma of the urothelium

New NICE guidance recommends not using Avastin for metastatic breast cancer

Stemline Therapeutics licenses phase I/II brain cancer vaccine

Enrollment complete in first of two pivotal phase III efficacy trials of LibiGel

CEQ-508 does not have adverse effects in nonhuman primates

AMG-386/sorafenib combination shows promise in metastatic renal cell carcinoma

MolMed extends pivotal phase III trial of NGR-hTNF

Phase II TXA-127 trial begins in autologous peripheral blood stem cell transplantation

PolyMedix completes phase I safety study of PMX-30063

Sanofi-aventis acquires BMP Sunstone

FDA grants Genentech hearing on Avastin for metastatic breast cancer

Belgian researchers disclose new inhibitors of HIV replication

Green Cross discloses (+)-3-hydroxymorphinans for neurodegenerative diseases

Takeda presents novel PARP inhibitors

New protein kinase inhibitors disclosed

Theravance presents new inhibitors of norepinephrine and/or 5-HT reuptake

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...